argenex (ARGX) Stock Forecast & Price Target

argenex
Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

• argenx SE demonstrated strong financial performance in its most recent quarterly report on July 21, 2026, where it reported earnings per share of $7.32, significantly exceeding the analyst consensus estimate of $5.86 by $1.46, while also generating revenue of $1.54 billion against expectations of $1.45 billion, indicating robust operational execution and profitability with a net margin of 32.19%.
• The company has maintained a consistent growth trajectory, having delivered 18 consecutive quarters of sales growth, which supports the current stock price of $963.79 and suggests that the market is valuing the firm based on sustained top-line expansion rather than one-time events.
• Wall Street analysts maintain a positive outlook on the stock, with a consensus rating of "Moderate Buy" and a consensus price target of $1,158.61 as of September 9, 2026, which implies potential upside from the current trading levels, supported by recent price target increases from firms like Morgan Stanley and Wells Fargo.
• Institutional investor confidence appears to be strengthening, as evidenced by recent filings where Squarepoint Ops LLC increased its holdings in argenx SE by 314.8% during the second quarter, and Tidal Investments LLC lifted its position by 97.8%, suggesting that large capital allocators are accumulating shares in the current market environment.
• The company is positioned for future catalysts through its pipeline, with expectations to report multiple pivotal clinical results through the second half of 2027, which could drive further valuation appreciation as new therapeutic candidates for autoimmune diseases progress through development.